Expression of Autophagy-Related Proteins in Different Types of Thyroid Cancer by 援ъ옄�듅 & 源��삙誘�
 International Journal of 
Molecular Sciences
Article
Expression of Autophagy-Related Proteins in
Different Types of Thyroid Cancer
Hye Min Kim, Eun-Sol Kim and Ja Seung Koo *
Department of Pathology, Yonsei University College of Medicine, Seoul 03722, Korea;
pinkmin15@yuhs.ac (H.M.K.); kesol13@yuhs.ac (E.-S.K.)
* Correspondence: kjs1976@yuhs.ac; Tel.: +82-2-2228-1772; Fax: +82-2-362-0860
Academic Editor: Yogesh Kumar Vashist
Received: 3 January 2017; Accepted: 24 February 2017; Published: 2 March 2017
Abstract: Thyroid cancer is common type of malignant tumor in humans, and the autophagy status
of such tumors may vary according to subtype. This study aimed to investigate the expression and
implications of the major autophagy-related molecules light chain (LC) 3A, LC3B, p62, and BNIP-3 in
human thyroid carcinoma. Tissue microarrays were constructed from 555 thyroid cancers (papillary
thyroid carcinoma (PTC): 342; follicular carcinoma (FC): 112; medullary carcinoma (MC): 70; poorly
differentiated carcinoma (PDC): 23; and anaplastic carcinoma (AC): 8) and 152 follicular adenomas
(FAs). Expression of autophagy-related molecules (LC3A, LC3B, p62, and BNIP-3) was detected
immunohistochemically, and the results were analyzed via comparison with clinicopathologic
parameters. Tumoral LC3A and LC3B expressions were the highest in MC (p < 0.001), whereas
stromal LC3A expression was higher in AC and PTC (p < 0.001). BNIP-3 expression was absent in
MC and AC (p = 0.013). Tumoral LC3A, LC3B, and p62 expressions were higher in conventional
type PTC, compared with those in the follicular variant. PTC with the BRAF V600E mutation
exhibited higher expression of all autophagy-related proteins relative to PTC without this mutation
(p < 0.05). BNIP-3 negativity was associated with capsular invasion in FC (p = 0.001), and p62
negativity was associated with lymph node metastasis in MC (p = 0.006). In a univariate analysis,
LC3B negativity was associated with shorter disease-free survival in PTC with the BRAF V600E
mutation (p = 0.024). We conclude that the expression of autophagy-related proteins differs according
to thyroid cancer subtype.
Keywords: autophagy; subtype; thyroid cancer; stroma; pathology
1. Introduction
Thyroid cancer is common type of malignant tumor, affecting approximately 1% of the total
population. Thyroid cancer manifests as several common subtypes, including papillary thyroid
carcinoma (PTC), follicular carcinoma (FC), medullary carcinoma (MC), poorly differentiated
carcinoma (PDC), and anaplastic carcinoma (AC). Notably, the cellular origin, clinical manifestation,
metastatic pattern, and clinical prognosis have been reported to differ depending on the subtype [1].
In the field of cancer research, autophagy, defined as the lysosomal degradation of cellular
components, has recently received considerable attention. Autophagy plays an important role in
homeostasis through the removal of dysfunctional or damaged cellular components and recycling of
necessary cellular components [2–5]. Among the various proteins involved in the autophagy process,
the following markers are commonly used to evaluate autophagic activity: light chain (LC) 3, which
participates in elongation and contributes to autophagosome formation [6–8]; p62, a scaffold protein
that transfers ubiquitinated proteins to the autophagosome [9,10]; and BCL2/adenovirus E1B 19 kDa
protein-interacting protein 3 (BNIP3), a mitochondrial autophagy (mitophagy) regulator [11].
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Given its role in homeostasis, autophagy acts as a double-edged sword in cancers. The high
metabolic demands of highly aggressive malignant tumors cannot be satisfied by angiogenesis
and/or aerobic glycolysis alone, leading to activation of the alternative metabolic pathway
in which cytoplasmic components are recycled via autophagy to provide a source of cellular
energy [12,13]. However, unrestrained autophagy eventually leads to cell death following the
progressive consumption of cellular constituents [14,15]. Accordingly, autophagy plays roles in
both tumor suppression and progression, and the autophagy status has been linked to the tumor
subtype in various types of cancer [16–20].
In human thyroid cancer, the autophagy status may similarly vary according to the tumor subtype.
However, previous studies regarding the expression of autophagy-related proteins in thyroid cancer
have not yielded clear results. Therefore, in this study, we investigated the expression of LC3A, LC3B,
p62, and BNIP-3, the major components of autophagy, in human thyroid carcinomas, as well as the
implications of these expression patterns.
2. Results
2.1. Basal Characteristics of Thyroid Cancer
In this study, we included 555 thyroid cancer cases, including 342 cases of PTC (other subtypes:
FC, 112; MC, 70; PDC, 23; and AC, 8). The basal characteristics of the PTC cases are listed in Table S1.
This group comprised 302 cases of conventional type and 40 cases of follicular variant disease, and
236 of the 342 cases (69.0%) harbored the BRAF V600E mutation. The FC group comprised 99 cases of
minimally invasive type and 13 cases of widely invasive type disease, for which the basal characteristics
are listed in Table S2. The basal characteristics of MC, PDC, and AC are presented in Table S3.
2.2. Expression of Autophagy-Related Proteins in Thyroid Cancer
We next evaluated the expression of autophagy-related proteins in thyroid cancers and observed
significant differences in tumoral LC3A (p < 0.001), stromal LC3A (p < 0.001), LC3B (p < 0.001), and
BNIP-3 (p = 0.016) expression patterns with respect to thyroid cancer subtype. Tumoral LC3A and
LC3B expression was highest in MC, whereas stromal LC3A expression was higher in AC and PTC.
BNIP-3 expression was negative in both MC and AC (Figure 1 and Table 1).
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Table 1. Expression of autophagy-related proteins according to histologic thyroid cancer subtype.
Parameters Totaln = 555 (%)
PTC
n = 342 (%)
FC
n = 112 (%)
MC
n = 70 (%)
PDC
n = 23 (%)
AC
n = 8 (%) p-Value
LC3A (T) <0.001
Negative 421 (75.9) 294 (86.0) 99 (88.4) 0 (0.0) 20 (87.0) 8 (100.0)
Positive 134 (24.1) 48 (14.0) 13 (11.6) 70 (100.0) 3 (13.0) 0 (0.0)
LC3A (S) <0.001
Negative 359 (64.7) 167 (48.8) 99 (88.4) 70 (100.0) 21 (91.3) 2 (25.0)
Positive 196 (35.3) 175 (51.2) 13 (11.6) 0 (0.0) 2 (8.7) 6 (75.0)
LC3B <0.001
Negative 283 (51.0) 146 (42.7) 99 (88.4) 14 (20.0) 20 (87.0) 4 (50.0)
Positive 272 (49.0) 196 (57.3) 13 (11.6) 56 (80.0) 3 (13.0) 4 (50.0)
P62 0.220
Negative 221 (39.8) 134 (39.2) 53 (47.3) 24 (34.3) 6 (26.1) 4 (50.0)
Positive 334 (60.2) 208 (60.8) 59 (52.7) 46 (65.7) 17 (73.9) 4 (50.0)
BNIP-3 0.016
Negative 494 (89.0) 297 (86.8) 100 (89.3) 70 (100.0) 19 (82.6) 8 (100.0)
Positive 61 (11.0) 45 (13.2) 12 (10.7) 0 (0.0) 4 (17.4) 0 (0.0)
PTC: papillary thyroid carcinoma; FC: follicular carcinoma; MC: medullary carcinoma; PDC: poorly differentiated
carcinoma; AC: anaplastic carcinoma; T: tumoral; S: stromal. Bold indicates statistically significant (p < 0.05).
We further evaluated the expression of autophagy-related proteins in PTCs according to the
histologic subtype and BRAF V600E mutation status. We found that tumoral LC3A (p = 0.026),
LC3B (p = 0.007), and p62 (p < 0.001) expression differed significantly according to the histologic
subtype. Higher tumoral LC3A, LC3B, and p62 expressions were observed in conventional type
tumors relative to follicular variant tumors. In addition, the expression of all autophagy-related
proteins differed significantly according to the BRAF V600E mutation status (p < 0.05); specifically, the
BRAF V600E mutation was associated with higher expression levels of all autophagy-related proteins
(Table 2 and Figure 2). In contrast, in an analysis of follicular neoplasms, no significant differences
were observed in the expression of autophagy-related proteins between FA and FC or between FC,
minimally invasive and FC, widely invasive (Tables 3 and 4).
Table 2. Expression of autophagy-related proteins according to histologic papillary thyroid
carcinoma subtype.
Parameters
Total
n = 342 (%)
Histologic Subtype
p-Value
BRAF V600E Mutation Status
p-ValueConventional
Type n = 302 (%)
Follicular Variant
n = 40 (%)
No Mutation
n = 106 (%)
Mutation
n = 236 (%)
LC3A (T) 0.026 0.002
Negative 294 (86.0) 255 (84.4) 39 (97.5) 100 (94.3) 194 (82.2)
Positive 48 (14.0) 47 (15.6) 1 (2.5) 6 (5.7) 42 (17.8)
LC3A (S) 0.133 0.031
Negative 167 (48.8) 143 (47.4) 24 (60.0) 61 (57.5) 106 (44.9)
Positive 175 (51.2) 159 (52.6) 16 (40.0) 45 (42.5) 130 (55.1)
LC3B 0.007 <0.001
Negative 146 (42.7) 121 (40.1) 25 (62.5) 68 (64.2) 78 (33.1)
Positive 196 (57.3) 181 (59.9) 15 (37.5) 38 (35.8) 158 (66.9)
p62 <0.001 <0.001
Negative 134 (39.2) 105 (34.8) 29 (72.5) 72 (67.9) 62 (26.3)
Positive 208 (60.8) 197 (65.2) 11 (27.5) 34 (32.1) 174 (73.7)
BNIP-3 0.327 <0.001
Negative 297 (86.8) 260 (86.1) 37 (92.5) 105 (99.1) 192 (81.4)
Positive 45 (13.2) 42 (13.9) 3 (7.5) 1 (0.9) 44 (18.6)
T: tumoral; S: stromal. Bold indicates statistically significant (p < 0.05).
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Table 3. Expression of autophagy-related proteins in follicular neoplasms.
Parameters Total n = 265 (%) FA n = 153 (%) FC n = 112 (%) p-Value
LC3A (T) 0.300
Negative 240 (90.6) 141 (92.2) 99 (88.4)
Positive 25 (9.4) 12 (7.8) 13 (11.6)
LC3A (S) 0.278
Negative 227 (85.7) 128 (83.7) 99 (88.4)
Positive 38 (14.3) 25 (16.3) 13 (11.6)
LC3B 0.221
Negative 226 (85.3) 127 (83.0) 99 (88.4)
Positive 39 (14.7) 26 (17.0) 13 (11.6)
p62 0.185
Negative 138 (52.1) 85 (55.6) 53 (47.3)
Positive 127 (47.9) 68 (44.4) 59 (52.7)
BNIP-3 0.946
Negative 237 (89.7) 137 (89.5) 100 (89.3)
Positive 28 (10.6) 16 (10.5) 12 (10.7)
FA: follicular adenoma; FC: follicular carcinoma; T: tumoral; S: stromal.
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Table 4. Expression of autophagy-related proteins according to histologic follicular carcinoma
(FC) subtype.
Parameters Total n = 112 (%) FC, Minimally InvasiveType n = 99 (%)
FC, Widely Invasive
Type n = 13 (%) p-Value
LC3A (T) 0.646
Negative 99 (88.4) 88 (88.9) 11 (84.6)
Positive 13 (11.6) 11 (11.1) 2 (15.4)
LC3A (S) 1.000
Negative 99 (88.4) 87 (87.9) 12 (92.3)
Positive 13 (11.6) 12 (12.1) 1 (7.7)
LC3B 0.651
Negative 99 (88.4) 11 (84.6) 88 (88.9)
Positive 13 (11.6) 2 (15.4) 11 (11.1)
p62 0.616
Negative 53 (47.3) 46 (46.5) 7 (53.8)
Positive 59 (52.7) 53 (53.5) 6 (46.2)
BNIP-3 0.354
Negative 100 (89.3) 87 (87.9) 13 (100.0)
Positive 12 (10.7) 12 (12.1) 0 (0.0)
T: tumoral; S: stromal.
2.3. Correlation Among the Expressions of Autophagy-Related Proteins
The results of the correlation analysis of the expression of LC3A, LC3B, p62, and BNIP3 showed
significant correlation between LC3A (T) and LC3A (S), LC3B, p62 and BNIP3 (r = −0.233, 0.255, 0.132,
0.138 respectively; all p < 0.001); between LC3A (S) and LC3B (r = 0.120; p < 0.001); between LC3A (S)
and p62 (r = 0.108; p < 0.001); between LC3B and p62 (r = 0.253; p < 0.001); between LC3B and BNIP3
(r = 0.058; p = 0.038); and between p62 and BNIP3 (r = 0.180; p < 0.001) (Table 5).
Table 5. Correlation among the expressions of autophagy-related proteins.
Parameters LC3A (T) LC3A (S) LC3B p62
LC3A (T)
Correlation coefficient - - - -
p-value - - - -
LC3A (S)
Correlation coefficient −0.233 - - -
p-value <0.001 - - -
LC3B
Correlation coefficient 0.255 0.120 - -
p-value <0.001 <0.001 - -
p62
Correlation coefficient 0.132 0.108 0.253 -
p-value <0.001 <0.001 <0.001 -
BNIP3
Correlation coefficient 0.138 0.029 0.058 0.180
p-value <0.001 0.297 0.038 <0.001
T: tumoral; S: stromal. Bold indicates statistically significant (p < 0.05).
2.4. Correlations between Clinicopathologic Factors and Autophagy-Related Protein Expression in
Thyroid Cancers
Furthermore, we evaluated the correlations between clinicopathologic factors and the expression
of autophagy-related proteins in thyroid cancers. In PTCs, p62 expression differed depending on the
stromal type (p = 0.002), whereas the proportion of tumors with positive p62 expression was higher
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among desmoplastic and inflammatory type tumors than among normal-like and sclerotic type tumors.
BNIP-3 negativity was associated with capsular invasion in FC (p = 0.001), and p62 negativity was
associated with lymph node metastasis in MC (p = 0.006) (Figure 3).Int. J. Mol. Sci. 2017, 18, 540 6 of 11 
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Table 6. Univariate analysis of the influences of autophagy-related protein expression on disease-free
and overall survival among patients with papillary thyroid cancer (log-rank test).
Parameter Number of Patients
/Recurrence/Death
Disease-Free Survival Overall Survival
Mean Survival
(95% CI) Months p-Value
Mean Survival
(95% CI) Months p-Value
LC3A (T) 0.717 0.327
Negative 294/16/14 106 (104–109) 108 (106–110)
Positive 48/2/4 106 (100–111) 103 (97–109)
LC3A (S) 0.923 0.216
Negative 167/9/6 107 (103–110) 109 (107–111)
Positive 175/9/12 105 (102–108) 104 (101–107)
LC3B 0.257 0.805
Negative 146/10/7 105 (101–109) 108 (105–111)
Positive 196/8/11 108 (105–110) 107 (105–110)
p62 0.643 0.140
Negative 134/8/4 105 (101–109) 108 (106–111)
Positive 208/10/14 107 (104–110) 106 (103–109)
BNIP-3 0.804 0.055
Negative 297/16/13 106 (104–109) 108 (106–110)
Positive 45/2/5 107 (101–113) 102 (95–110)
CI: confidence interval; T: tumoral; S: stromal.
3. Discussion
In this study, we investigated the expression of autophagy-related proteins in thyroid cancers and
confirmed the existence of different expression patterns according to disease subtype. For example,
we observed significantly higher levels of tumoral LC3A and LC3B expression in MC, a finding
that was corroborated by a previous study in which higher expression levels of autophagy-related
molecules, such as beclin-1 and LC3B, were observed in a MC cell line [21]. According to that earlier
study, sporadic type and hereditary type MCs differed with respect to the autophagy status, and higher
expression levels of autophagy-related molecules were observed in the former [21]. The different
autophagy statuses observed in MC, compared to other types of thyroid cancer, might be attributable
to differences in the expression of micro-RNAs (miRNAs), which have been reported to regulate
autophagic activity in MC [21]. In addition, differences in miRNA expression profiles have been
observed among different thyroid cancer subtypes [22]. Therefore, autophagic activity may differ as a
result of distinct miRNA expression patterns, although this will require additional studies.
In our analysis of PTC, we observed differences in autophagy-related protein expression according
to the BRAF V600E mutation status. Specifically, higher expression levels of all autophagy-related
proteins were observed in PTCs with the BRAF V600E mutation, compared to those without the BRAF
V600E mutation. In support of this finding, previous studies have observed an association between
the BRAF V600E mutation and increased autophagy [23,24]. This association may be attributed
to multiple factors. First, chronic ER stress may play a mechanistic role. Following activation of
the IRE1/ASK1/JNK and TRB3 pathways via BRAF V600E-mediated p38 activation, Bcl-XL/Bcl-2
phosphorylation, induced by active JNK, and Akt/mTOR axis inhibition, mediated by TRB3, lead
to increased autophagic activity [24]. Second, long non-coding RNAs (lncRNAs) may also play a
mechanistic role. For example, an increase in the LC3-II/LC3-I that was mediated by BRAF-activated
lncRNA was found to induce autophagy in a previous study [23].
Our results further demonstrated a high level of stromal LC3A expression in PTC. Previously,
stromal LC3A expression was also observed in breast cancer [18], similar to the findings of this
study. The expression of autophagy-related proteins in tumor stroma has been attributed to a
“reverse Warburg” effect, wherein a metabolic interaction exists between breast cancer cells and stromal
cells. According to this theory, glycolysis, mitochondrial dysfunction, and increased autophagy activity
are induced in stromal cells by reactive oxygen species produced by breast cancer cells. Ketone bodies
and lactate, the by-products of glycolysis in stromal cells, enter cancer cells and facilitate the production
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of ATP through oxidative phosphorylation [25–27]. Therefore, according to the reverse Warburg effect,
autophagic activity would increase in stromal cells, which corresponds with the increased expression
of LC3A and LC3B in PTC tumor stroma. In this context, cancer-associated fibroblasts that express
reduced levels of caveolin-1 serve as tumor cell-interacting stromal cells [28,29]. In a previous study of
thyroid cancer, the reported proportion of caveolin-1-negative stroma was 78.9% [30], suggesting that
the reverse Warburg effect may describe the situation in PTC. However, further studies are needed to
clarify this potential mechanism.
We note that one limitation of our study was the use of immunohistochemistry (IHC) to detect
autophagy-related proteins (beclin-1, LC3A, and LC3B) as an indicator of autophagic activity. Because
autophagy is a dynamic, multi-step process, a static measure of autophagy activity (e.g., IHC) may yield
inaccurate results. Namely, as the autophagy-related proteins LC3A and LC3B are autophagosome
components, the increased expression of these proteins could be interpreted as an increase in the
number of autophagosomes and, therefore, in autophagic activity. However, an increased number of
autophagosomes might also result from delayed degradation. Therefore, an analysis of autophagy
flux, which indicates changes in autophagic stages, would yield a more accurate measurement of
autophagic activity [10]. However, it was impossible to evaluate autophagy flux in our IHC study of
paraffin-embedded tumor samples.
Clinically, the results of our study imply that autophagy regulation should be considered as a
potential cancer therapeutic target. Recent evidence suggests that treatment with autophagy inhibitors
could inhibit the growth of various tumors [31–34]. Specifically, autophagy inhibition might provide
insights into the treatment of MC, which expresses high levels of autophagy markers and for which an
effective target therapy is not currently available.
4. Materials and Methods
4.1. Patient Selection and Study Design
This study included patients with diagnosed PTC who underwent surgery at Severance Hospital
between January 2012 and December 2013, as well as patients diagnosed with other thyroid cancer
subtypes following surgery at Severance Hospital between January 2000 and December 2014. Patients
who received preoperative chemotherapy were excluded. The study protocol was approved by the
Institutional Review Board of Yonsei University Severance Hospital (8 November 2016; 4-2016-0832).
All cases of thyroid cancer were reviewed retrospectively by a single thyroid pathologist
(Ja Seung Koo) via a histologic review of hematoxylin and eosin (H&E)-stained slides.
Clinicopathologic data were obtained from the patients’ medical records and included the age at
diagnosis, disease recurrence, metastasis status, current status, and duration of follow-up. The tumor
size, location (right or left lobe), extent (confined to the thyroid parenchyma or with extrathyroidal
spread), and number of metastatic lymph nodes were also determined from the histologic review of
tumor slides and surgical pathology reports.
4.2. Tissue Microarray
Representative areas on (H&E)-stained slides were selected, and corresponding spots were marked
on the surfaces of matching paraffin blocks. Three-millimeter sized tissue cores were extracted by
using a manual tissue arrayer from the selected areas and placed into a 6 × 5 recipient block. More
than two tissue cores were extracted from each case to minimize extraction bias. Each tissue core was
assigned a unique tissue microarray location number that was linked to a database containing other
clinicopathologic data.
4.3. Immunohistochemistry
The antibodies used for (IHC) are listed in Table 7. All IHC analyses were performed
using formalin-fixed, paraffin-embedded tissue sections. Briefly, 5-µm-thick sections were
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obtained with a microtome, transferred onto adhesive slides, and dried at 62 ◦C for 30 min.
After incubation with primary antibodies, immunodetection was performed using biotinylated
anti-mouse immunoglobulin followed by peroxidase-labeled streptavidin, using a labeled streptavidin
biotin kit with 3,3′-diaminobenzidine chromogen as the substrate. The primary antibody incubation
step was omitted from the negative control. A positive control tissue was used per the manufacturer’s
recommendation. Slides were counterstained with Harris hematoxylin.
Table 7. Sources, clones, and dilutions of antibodies used for immunohistochemistry.
Antibody Clone Dilution Company
LC3A EP1528Y 1:100 Abcam, Cambridge, UK
LC3B Polyclonal 1:100 Abcam, Cambridge, UK
p62 SQSTM1 1:100 Abcam, Cambridge, UK
BNIP-3 Ana40 1:100 Abcam, Cambridge, UK
BRAF V600E VE1 1:50 Ventana, Tucson, AZ, USA
4.4. Interpretation of Immunohistochemical Staining
Immunohistochemical marker expression was visualized using light microscopy. Stained slides
were evaluated semi-quantitatively according to a previously reported method [35]. Tumor and stromal
cell staining were assessed using the following scoring system: 0, negative or weak immunostaining in
<1% of the tumor/stroma; 1, focal expression in 1%–10% of the tumor/stroma; 2: positive staining in
11%–50% of the tumor/stroma; and 3: positive staining in 51%–100% of the tumor/stroma. The entire
tumor area was subjected to assessment, and a score of ≥2 was defined as positive. BRAF V600E
staining was considered positive when more than 20% tumor cells were positive, as previously
described [36].
4.5. Statistical Analysis
Data were analyzed using IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp. Released
2012. Armonk, NY, USA). For determinations of statistical significance, Student’s t-test and Fisher’s
exact test were used for continuous and categorical variables, respectively. The correlation between the
expression of GLS1, GDH, and ASCT was analyzed using Kendall’s tau. To analyze data with multiple
comparisons, a corrected p-value and the Bonferroni multiple comparison procedure were applied.
Statistical significance was set at a p-value < 0.05. Kaplan–Meier survival curves and log-rank statistics
were used to evaluate the time to tumor recurrence and overall survival. A Cox proportional hazards
model was used for the multivariate regression analysis.
5. Conclusions
In conclusion, our combined data indicate that the expression of autophagy-related proteins
in thyroid cancers differs according to the subtype and, among PTCs, the BRAF V600E mutation
status. These findings, which corroborate the results of earlier studies, may lead to improvements and
developments in the field of target therapy for thyroid cancer.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/18/3/540/s1.
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